About Kalos Therapeutics

About company

Kalos Therapeutics is an emerging biomedical company with the exclusive patent to develop the ANP (atrial natriuretic peptide) family of peptides as a new mechanism for the treatment of cancer. Kalos is aggressively targeting diseases caused by an abnormally high growth rate of cells (hyperproliferation). Kalos is pioneering an approach to cancer treatment by developing peptides made primarily in the heart, as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small molecule compounds.